Loss of T790M mutation is associated with early progression to osimertinib in Chinese patients with advanced NSCLC who are harboring EGFR T790M
Lung cancer is the leading cause of cancer-related deaths worldwide[1]. With improved understanding of the molecular pathogenesis driving tumor progression, the clinical management for lung cancer has been revolutionized in recent years. Somatic mutations in epidermal growth factor receptor gene (EGFR) are common drivers of non-small cell lung cancer (NSCLC). EGFR tyrosine kinase inhibitors (TKIs), such as gefitinib, erlotinib and afatinib, demonstrate prominent efficacy in patients with advanced or recurrent nonsquamous NSCLC who harbor activating EGFR mutations and have been established as first-line therapies for patients in this subgroup [2 –5].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Sha Zhao, Xuefei Li, Chao Zhao, Tao Jiang, Yijun Jia, Jinpeng Shi, Yayi He, Jiayu Li, Fei Zhou, Guanghui Gao, Wei Li, Xiaoxia Chen, Chunxia Su, Shengxiang Ren, Caicun Zhou Source Type: research
More News: Cancer | Cancer & Oncology | China Health | Genetics | Lung Cancer | Non-Small Cell Lung Cancer | Tarceva